TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Saniona AB ( (SE:SANION) ).
Saniona has announced the selection of SAN2668 as a first-in-class clinical candidate for pediatric epilepsy, showcasing its potential to address significant unmet needs in children with difficult-to-treat epilepsy syndromes. SAN2668 has demonstrated strong efficacy and improved tolerability in preclinical models, positioning it to advance towards early proof-of-concept studies. This development reflects Saniona’s strategy to provide transformative medicines for rare epilepsies, aiming to overcome challenges associated with current treatments.
The most recent analyst rating on (SE:SANION) stock is a Hold with a SEK15.50 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.
More about Saniona AB
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company collaborates with leading pharmaceutical firms and has a diverse pipeline that includes treatments for epilepsy, major depressive disorder, and rare eating disorders.
Average Trading Volume: 1,114,398
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.7B
Learn more about SANION stock on TipRanks’ Stock Analysis page.